吉沃西兰 (Givosiran):一种针对性治疗急性间歇性病的治疗方法
Amy K Dickey1,2, Rebecca K Leaf2,3
1Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA.
Hematology. American Society of Hematology. Education Program
|December 7, 2024
概括
吉沃西兰通过降低关键疾病标志物和减少发作频率,有效治疗急性肝脏 (AHPs). 长期的研究和现实世界的数据证实了其在治疗这种罕见的遗传疾病方面的持续有效性和安全性.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性肝脏 (AHP) 是一种罕见的遗传性疾病,其特征是严重的神经瘤发作.
- 血液合成途径的缺陷,特别是ALAS1的诱导,导致AHP发作.
- 吉沃西兰是一种RNA干扰疗法,向肝脏ALAS1治疗AHPs.
研究的目的:
- 审查支持givosiran被批准用于AHP治疗的临床证据.
- 讨论关于givosiran的有效性和安全性的现实数据.
- 确定AHP管理中的剩余问题.
主要方法:
- 在AHP患者中对givosiran进行关键的第三期临床试验数据的审查.
- 对长期随访研究的分析,评估持续的疗效和生活质量.
- 从临床实践中检查现实世界的证据.
主要成果:
- 吉沃西兰显著降低了AHP攻击率和疾病生物标志物 (ALA和PBG) 的水平.
- 长期和现实世界的数据证实了持续的临床益处和改善的生活质量.
- 常见的副作用包括注射部位反应和生化异常.
结论:
- 吉沃西兰是一种有效的针对性治疗AHP,得到了强大的临床试验和现实世界的数据的支持.
- 持续监测诸如高血糖蛋白质血症等副作用是很重要的.
- 需要进一步的研究来解决AHP治疗中的剩余问题.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
357
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
357
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115


